Satish Chaudhary, Reetesh Sharma, Saumya Gupta, Sita Paikra, Mohit Gupta, Bal K Upadhyay, Alok Sharma, Rajiv K Sethia
{"title":"Successful Reversal of Refractory Posttransplant Thrombotic Microangiopathy with Eculizumab.","authors":"Satish Chaudhary, Reetesh Sharma, Saumya Gupta, Sita Paikra, Mohit Gupta, Bal K Upadhyay, Alok Sharma, Rajiv K Sethia","doi":"10.4103/ijn.ijn_345_22","DOIUrl":null,"url":null,"abstract":"<p><p>Posttransplant thrombotic microangiopathy (PT-TMA) can be caused by calcineurin inhibitors (CNIs), ischemic injury, infections, or antibody-mediated rejection (ABMR). Delayed recognition can result in allograft loss. We describe the first reported case of successful reversal of refractory PT-TMA with eculizumab in India. It highlights the importance of prompt diagnosis and benefit from an early initiation of eculizumab therapy in refractory cases.</p>","PeriodicalId":13359,"journal":{"name":"Indian Journal of Nephrology","volume":"34 2","pages":"191-194"},"PeriodicalIF":0.8000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11044662/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indian Journal of Nephrology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/ijn.ijn_345_22","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/4/4 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Posttransplant thrombotic microangiopathy (PT-TMA) can be caused by calcineurin inhibitors (CNIs), ischemic injury, infections, or antibody-mediated rejection (ABMR). Delayed recognition can result in allograft loss. We describe the first reported case of successful reversal of refractory PT-TMA with eculizumab in India. It highlights the importance of prompt diagnosis and benefit from an early initiation of eculizumab therapy in refractory cases.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
